Breast Cancer

Plinabulin demonstrated similar efficacy to pegfilgrastim for the prevention of chemotherapy-induced neutropenia, according to results of a randomized phase 3 study published in JAMA Network Open.

In this video, Debu Tripathy, MD, discussed the role of oral selective estrogen receptor down regulators in treating breast cancer patients with ESR1 mutations.

Although much remains unknown about the impact of COVID-19 on people with cancer, the impact on screening is becoming clearer.

The use of current standard HER2 assays as diagnostic tests may result in misassignment of patients for treatment of breast cancer with trastuzumab deruxtecan, according to a study published in JAMA Oncology.

The FDA granted fast track designation to Bria-IMT, an investigational cell-based therapy for the treatment of women with metastatic breast cancer.

Study results showed that women with breast cancer had a greater risk for CVD events, including heart failure and cardiomyopathy, than women without breast cancer.

An artificial intelligence model appeared to predict adverse events associated with novel combination therapies for various cancer types, according to study results presented at American Association for Cancer Research Annual Meeting.

A substantial portion of ductal carcinoma in situ recurrences did not appear genetically related to their primary lesions, according to study findings presented at American Association for Cancer Research Annual Meeting.

Younger women with nonmetastatic breast cancer who underwent breast-conserving surgery experienced similar OS as those who underwent mastectomy, according to study results.

COVID-19 restrictions led to a 1.2-fold increase in presentation of late-stage breast cancer at an urban safety-net hospital, according to a study presented at an American Society of Breast Surgeons Annual Meeting press briefing.